Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.20.4
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Expenses        
Research and development $ 2,584 $ 712 $ 3,941 $ 1,434
General and administrative 2,794 1,054 4,329 1,967
Merger costs     500  
In-process research and development     16,094  
Operating Expenses 5,378 1,766 24,864 3,401
Other (income) loss        
Foreign exchange loss 3 2 2 2
Amortization of deferred loan costs 25   51  
Interest expense 8   16  
Interest income (1) (28) (2) (57)
Other loss (income) 35 (26) 67 (55)
Net loss for the period 5,413 1,740 24,931 3,346
Computation of basic loss per share        
Net loss for the period 5,413 1,740 24,931 3,346
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance     3,181  
Series A Preferred cash dividend 2 2 4 4
Series B Preferred stock dividend 4 3 9 5
Net loss for the period attributable to common stockholders $ 5,419 $ 1,745 $ 28,125 $ 3,355
Basic and fully diluted loss per share $ 0.22 $ 0.15 $ 1.34 $ 0.35
Basic and fully diluted weighted average number of shares 24,845,000 11,408,000 20,976,000 9,473,000